IN BRIEF: Genedrive included in Public Health England framework

Mon, 19th Apr 2021 12:46

Genedrive PLC - Manchester-based molecular diagnostics firm - Wins Public Health England deal under Lot 1 of National Microbiology Framework. Lot 1 relates to supply of diagnostic goods and services. "The award of a framework contract is not exclusive to the company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future," Genedrive says.

Current stock price: 73.36 pence, up 9.5% on Monday

Year-to-date change: up 51%

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

10 May 2024 12:10

IN BRIEF: Genedrive completes placing portion of GBP6 million raise

Genedrive PLC - Manchester-based pharmacogenetic testing - Completes placing of 138.8 million new shares at 1.5 pence each, raising GBP2.1 million. Th...

10 May 2024 10:59

AIM WINNERS & LOSERS: Polarean wins deal; Genedrive completes placing

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

10 May 2024 07:00

IN BRIEF: Genedrive aims to raise at least GBP6 million in share offer

Genedrive PLC - Manchester-based pharmacogenetic testing company - Seeks to raise a minimum of GBP6.0 million from an offer of new shares at 1.5 pence...

24 Apr 2024 17:26

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulator...

3 Apr 2024 16:54

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory ac...